Clinical Research

Active Studies

Manage studies
39 recruiting
10 coming soon
5 active, not recruiting

Filter by area

All(60)Glomerulonephritis(11)Pre-dialysis CKD(11)Polycystic kidney disease(1)Genetic Kidney Disease(8)Hemodialysis(18)Peritoneal dialysis(1)Transplant – eligibility and preparation(1)Transplant – perioperative(4)Transplant – post-transplant care(6)Perioperative care (non-transplant)(1)
Showing 2 studies in Polycystic kidney disease
Currently Recruiting1 study

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease (MAPLE)

Polycystic kidney disease, Genetic Kidney Disease · GlaxoSmithKline

Pavel RoshanovPavel Roshanov

This Phase 1a/1b randomized, double-blind, placebo-controlled trial evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK4771261. Part A assesses single ascending doses in healthy participants to determine the drug's safety profile and systemic impact. Part B investigates the intervention in patients with autosomal dominant polycystic kidney disease (ADPKD) to establish initial clinical data in the target population. The study monitors standard safety parameters and physiological responses to inform future dosing strategies for chronic kidney disease management.

Completed1 study

Canadian Medical Assessment of JINARC™ Outcomes Registry (C-MAJOR)

Polycystic kidney disease · Otsuka Canada Pharmaceutical Inc.

Matthew WeirMatthew Weir

This observational, non-interventional cohort study evaluates the real-world impact of tolvaptan in Canadian patients with ADPKD. The study assesses the burden of illness through patient-reported outcome questionnaires and tracks clinical progression to RRT, including dialysis and transplantation. Researchers monitor long-term mortality rates and specific causes of death, with a focus on renal and hepatic outcomes. The target population consists of ADPKD patients prescribed tolvaptan as part of routine clinical care following Health Canada approval.